MedPath
HSA Approval

NEFEGAN MODIFIED RELEASE CAPSULE 4MG

SIN16972P

NEFEGAN MODIFIED RELEASE CAPSULE 4MG

NEFEGAN MODIFIED RELEASE CAPSULE 4MG

March 19, 2024

EVEREST MEDICINES (SINGAPORE) PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantEVEREST MEDICINES (SINGAPORE) PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

CAPSULE

ORAL

Medical Information

A07EA06

budesonide

Manufacturer Information

EVEREST MEDICINES (SINGAPORE) PTE. LTD.

Patheon Pharmaceuticals Inc.

Active Ingredients

Budesonide

4.00 mg

Budesonide

Documents

Package Inserts

Nefegan capsule PI.pdf

Approved: March 19, 2024

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

NEFEGAN MODIFIED RELEASE CAPSULE 4MG - HSA Approval | MedPath